Please login to the form below

Not currently logged in
Email:
Password:

darapladib

This page shows the latest darapladib news and features for those working in and with pharma, biotech and healthcare.

GSK takes anti-inflammatory drug into phase III as heart therapy

GSK takes anti-inflammatory drug into phase III as heart therapy

GSK's cardiovascular pipeline suffered a setback last month when coronary artery disease therapy darapladib failed a second phase III trial.

Latest news

  • Second darapladib failure disappoints GSK Second darapladib failure disappoints GSK

    Drug unable to demonstrate effectiveness in acute coronary syndrome. Prospects for GlaxoSmithKline's coronary artery disease therapy darapladib have all but disappeared after it failed to show efficacy in a second ... Top-line results from the SOLID-TIMI

  • Moving parts Moving parts

    Meanwhile, costly phase III failures arrived in the shape of Lilly's depression drug edivoxetine and GlaxoSmithKline's highly anticipated new coronary heart disease drug candidate darapladib, which both flunked

  • GSK hit as darapladib flunks phase III test GSK hit as darapladib flunks phase III test

    Heart disease drug disappoints in late-stage trial.  . GlaxoSmithKline's highly anticipated new coronary heart disease (CHD) drug candidate darapladib has disappointed in a phase III trial. ... will continue to examine the data and wait for the results

  • GSK's Chinese sales hit by scandal, say analysts GSK's Chinese sales hit by scandal, say analysts

    darapladib for atherosclerosis which could have "vast potential" if it reaches the market.

  • GSK submits albiglutide for European approval GSK submits albiglutide for European approval

    Albiglutide is, along with lupus treatment Benlysta and heart disease drug darapladib, one of a trio of drugs GSK has developed with Human Genome Sciences.

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Pharma deals during July 2012 Pharma deals during July 2012

    These are Benlysta (belimumab), an antibody approved for the treatment of lupus; darapladib, a phase III small molecule drug for the treatment of cardiovascular disease; and albiglutide, an albumin-fusion protein ... There is $150m in potential licence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics